IKNA
ImageneBio Inc
$
17.640
- Overview
- Forecast
- Valuation
- Earnings
High
17.640
Open
17.640
VWAP
--
Vol
--
Mkt Cap
84.45M
Low
17.640
Amount
--
EV/EBITDA(TTM)
--
Total Shares
48.26M
EV
-26.63M
EV/OCF(TTM)
--
P/S(TTM)
--
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Show More
1 Analyst Rating
-77.32% Downside
Wall Street analysts forecast IKNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKNA is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
-77.32% Downside
Current: 17.640
Low
4.00
Averages
4.00
High
4.00
-77.32% Downside
Current: 17.640
Low
4.00
Averages
4.00
High
4.00
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$4
2024-11-11
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$4
2024-11-11
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for ImageneBio Inc (IKNA.O) is -0.70, compared to its 5-year average forward P/E of -3.52. For a more detailed relative valuation and DCF analysis to assess ImageneBio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.52
Current PE
-0.70
Overvalued PE
-0.58
Undervalued PE
-6.47
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.82
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.72
Undervalued EV/EBITDA
-3.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
7.17
Current PS
0.00
Overvalued PS
14.45
Undervalued PS
-0.12
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
-42.21%
-8.75M
Operating Profit
FY2025Q2
YoY :
-79.85%
-2.77M
Net Income after Tax
FY2025Q2
YoY :
-78.57%
-0.06
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
10.5M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 604.46% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
762.6K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
7.9M
Volume
Months
6-9
1
1.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
10.5M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IKNA News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
09:02:15
iKena Oncology appoints Yarema as CEO of ImageneBio
2025-07-15 (ET)
2025-07-15
16:23:07
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger
2025-07-11 (ET)
2025-07-11
08:03:18
iKena says ISS, Glass Lewis recommends stockholders vote for merger
Sign Up For More Events
Sign Up For More Events
News
2.0
07-27TipRanksUpcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
8.5
07-25NewsfilterInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
8.5
07-15NewsfilterIkena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Sign Up For More News
People Also Watch
VTGN
Vistagen Therapeutics Inc
2.860
USD
0.00%
TLSA
Tiziana Life Sciences Ltd
2.270
USD
+2.02%
METCB
Ramaco Resources Inc
14.900
USD
0.00%
ADAG
Adagene Inc
2.190
USD
+14.66%
AMTD
AMTD IDEA Group
0.930
USD
-2.11%
VFF
Village Farms International Inc
2.550
USD
+2.82%
DIT
Amcon Distributing Co
109.380
USD
0.00%
AGEN
Agenus Inc
4.599
USD
-4.39%
FAQ
What is ImageneBio Inc (IKNA) stock price today?
The current price of IKNA is 17.64 USD — it has increased 4.2 % in the last trading day.
What is ImageneBio Inc (IKNA)'s business?
What is the price predicton of IKNA Stock?
What is ImageneBio Inc (IKNA)'s revenue for the last quarter?
What is ImageneBio Inc (IKNA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ImageneBio Inc (IKNA)'s fundamentals?
How many employees does ImageneBio Inc (IKNA). have?